Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors

Producción científica: Review article › revisión exhaustiva

14 Citas (Scopus)

Resumen

The protein kinase, p38α MAPK, is a key intracellular transducer of stressor-induced neuroinflammatory responses and, as such, is of high interest as a potential therapeutic target. We recently reported the synthesis and evaluation of first-in-class CNS-penetrant and highly specific p38 MAPK inhibitors that avoid target crossover issues seen in popular small molecule p38 MAPK inhibitors used in hundreds of previous reports. The novel p38 MAPK inhibitors, represented in this study by MW181, are efficacious in vivo. Pharmacodynamic actions include attenuation of stressor-induced increases in brain proinflammatory cytokine levels. We report here more detailed analyses of MW181 target engagement and specific linkage to the downstream increase in glia proinflammatory cytokine production. In vivo validation included demonstration that oral administration of MW181 suppresses lipopolysaccharide-induced increases in mouse brain IL-1β, TNFα, IL-6, IL-10, and CXCL1 but not in a drug-resistant p38α MAPK mutant mouse.

Idioma originalEnglish
Páginas (desde-hasta)454-460
Número de páginas7
PublicaciónJournal of NeuroImmune Pharmacology
Volumen9
N.º4
DOI
EstadoPublished - sept 2014

Nota bibliográfica

Funding Information:
Acknowledgments We thank Danielle Goulding for excellent technical assistance. This research was supported in part by funding from the Alzheimer’s Drug Discovery Foundation (DMW), and NIH grants R01 AG031311 (DMW), U01 AG043415 (DMW), and R01 NS064247 (LVE). ADB was supported in part by NIH/NIA (F32 AG037280 and K99AG044445).

Financiación

Acknowledgments We thank Danielle Goulding for excellent technical assistance. This research was supported in part by funding from the Alzheimer’s Drug Discovery Foundation (DMW), and NIH grants R01 AG031311 (DMW), U01 AG043415 (DMW), and R01 NS064247 (LVE). ADB was supported in part by NIH/NIA (F32 AG037280 and K99AG044445).

FinanciadoresNúmero del financiador
DMW
National Institutes of Health (NIH)R01NS064247, U01 AG043415
National Institute on AgingR01AG031311, K99AG044445, F32AG037280
Alzheimer's Drug Discovery Foundation

    ASJC Scopus subject areas

    • Neuroscience (miscellaneous)
    • Immunology and Allergy
    • Immunology
    • Pharmacology

    Huella

    Profundice en los temas de investigación de 'Target engagement analysis and link to pharmacodynamic endpoint for a novel class of CNS-penetrant and efficacious p38α MAPK inhibitors'. En conjunto forman una huella única.

    Citar esto